ShowcasesPricing
  1. US-listed companies
  2. PRESSURE BIOSCIENCES INC

PRESSURE BIOSCIENCES INCPBIO

Market cap
$2.6M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
Cash and cash equivalents1,46131,417473,948116,783138,36381,033103,11829,62518,540132,3113,865
Accounts receivable216,265147,635272,022113,256281,320206,848474,830229,402131,228154,746295,374
Inventories, net of $982,973 and $342,496 reserve, respectively923,362736,676850,5521905,284857,662765,478617,716592,7671686,383
Prepaid expenses and other current assets83,43585,573104,204213,926258,103214,676170,734213,549314,936422,617257,527
Total current assets11212121121
Investment in equity securities------16,64316,643517,00159,97663,638
Property and equipment, net30,28258,10236,02520,1499,41322,66269,27255,59016,490115,846103,351
Right of use asset operating leases-------76,586221,432395,565282,095
Intangible assets, net85,13036,498---750,000663,462576,923490,385403,846317,308
TOTAL ASSETS11222222232
Accounts payable111941,389407,249589,263658,856815,764771,945527,924637,238
Accrued employee compensation119,338149,333157,347176,009249,596368,700456,932451,200417,578117,680167,247
Accrued professional fees and other--------222
Accrued interest and dividends payable----------11
Deferred revenue46,46628,18927,117140,878159,654263,106--47,32837,12458,242
Convertible debt, net of unamortized debt discounts of $455,517 and $1,536,649, respectively---100,000484681318
Other debt, net of unamortized discounts of $0 and $0, respectively---151,628238,1571852,3152112
Related party debt, net of unamortized debt discount of $7,915 and $0, respectively98,675---------634,885
Right of use operating lease liability-------76,58665,193132,996142,171
Total current liabilities33410917814192534
Long term debt--------527,039150,000150,000
Right of use operating lease liability long term--------156,239262,569139,924
Deferred revenue2,4872,78528,97736,93587,52757,14937,75718,06519,3823,5871,822
TOTAL LIABILITIES334101017914192535
Series D, G, H, H2, J, K, AA Convertible Preferred Stock, $.01 par value (Note 10)----------1,098
Common stock, $.01 par value; 100,000,000 shares authorized; 13,682,910 and 9,120,526 shares issued and outstanding on December 31, 2022 and December 31, 2021, respectively121,493120,243186,734230,050309,99813,42916,84225,49641,68391,206136,829
Warrants to acquire common stock----------32
Additional paid-in capital1620252627314044506469
Accumulated deficit-20,619,539-25,866,988-32,118,714-39,557,206-42,264,190-55,349,299-65,727,538-78,942,277-96,465,807-118,277,468-133,826,205
TOTAL STOCKHOLDERS’ DEFICIT-1,539,776-1,967,775-2,059,731-7,977,648-8,383,418-14,622,796-6,125,071-12,055,407-16,917,592-22,208,961-32,686,371
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT11222222232